Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response

Neoplasma

Volumn 49, Issue 3, 2002, Pages 159-166

  Lauerova L ^a   Dusek L ^a   Simickova M ^a   Kocak I ^a   Vagundova M ^a   Zaloudik J ^a   Kovarik J ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

Author keywords

Cytokines; Immunotherapy; Malignant melanoma; Th1 Th2 response

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 6; RECOMBINANT ALPHA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MELANOMA; POSTOPERATIVE PERIOD; TH1 CELL; TH2 CELL;

EID: 0036305649     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Anti-transforming growth factor (TGF)-beta-antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity
2. Quantitative analysis of Th1 Th2 and TGF-beta 1 cytokine expression in tumor TIL and PBL of non-small cell lung cancer patients
3. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma analysis of 270 patients treated between 1985 and 1993
4. Transforming growth factor beta mRNA expression and growth control of human ovarian carcinoma cells
5. Correlation between clinical response to interleukin-2 therapy and sustained production of tumor necrosis factor
6. Immunosuppression and transforming growth factor beta in glioblastoma
7. Soluble interleukin-2 receptor intercellular adhesion molecule-1 and interleukin-10 serum levels in patients with melanoma
8. Gene therapy of cancer use of IL-2 transfer and kinetics of local T and NK cell subsets
9. Gene therapy of plasmacytoma comparison of the therapeutic efficacy of tumour cells transduced with the interleukin-2 interleukin-4 or interleukin-6 genes
10. Production of transforming growth factors by human colon cancer lines
11. Th1 and Th2 cytokine response patterns in leukocyte cultures of patients with urinary bladder renal cell and prostate carcinomas
12. Metastatic renal-cell carcinoma patients treated with interleukin 2 or interleukin 2 plus interferon gamma immunological monitoring
13. Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients
14. Unexpected cytokines in serum of malignant melanoma patients during sequential biochemotherapy
15. Biological monitoring of low-dose interleukin in humans soluble interleukin 2 receptors cytokines and cell surface phenotypes
16. Cellular immunity
17. The role of TNF-alpha in T-cell-mediated inflammation depends on Th1/Th2 cytokine balance
18. Decreased frequency of interferon gamma and interleukin-2-producing cells in patients with atopic diseases measured at the single cell level
19. Serum levels of tumor necrosis factor-alpha and nutritional status in pancreatic cancer patients
20. Tumor necrosis factor and lymphotoxin gene expression in human tumor cell lines
21. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy
22. Role of recombinant interleukin-2 in combination with interferon-α and chemotherapy in the treatment of advanced melanoma
23. Type 1 and type 2 cytokine dysregulation in human infections neoplastic and inflammatory diseases
24. Natural killer cell stimulatory factor (Interleukin 12 (IL-12)) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells
25. Efficacy of continuous subcutaneous infusion therapy using interferon alpha and the possible prognostic indicator of TNF-alpha in renal cell carcinoma
26. Single-cell analysis of IL-4 and IFN-γ production by T cells from HIV-infected individuals decreased IFN-γ in the presence of preserved IL-4 production
27. Serum imbalance of cytokines in melanoma patients
28. The IL-4 receptor signaling mechanisms and biologic functions
29. Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients
30. Evaluation of methods for calculating confidence intervals about the mean of a log-normally distributed variable
31. Analysis of lognormal data
32. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression
33. Interleukin 2 and interleukin 15 differentially predispose natural killer cells to apoptosis mediated by endothelial and tumour cells
34. Predominance of a type 2 intratumoral immune response in fresh tumour-infiltrating lymphocytes from human gliomas
35. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A/MART-1
36. Impaired production of Th1 cytokines and increased frequency of Th2 subsets in PBMC from advanced cancer patients
37. Molecular regulation of human interleukin 2 and T-cell function by interleukin 4
38. Acquisition of lymphokine-producing phenotype by CD4+ T cells
39. Predominance of Th1 response in tumor-bearing mice and cancer patients treated with AS101
40. Regulation of the interleukin (IL)-12R beta 2 subunit expression in developing T helper 1 (Th1) and Th2 cells
41. Th2-like response and antitumour effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma
42. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients
43. IL-6 is a survival prognostic factor in renal cell carcinoma
44. Interleukin 12 and tumor necrosis factor α are costimulators of interferon γ production by natural killer cells in severe combined immunodeficiency mice with listeriosis and interleukin-10 is a physiologic antagonist
45. Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis
46. Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor